Loading...

SRPT SAREPTA THERAPEUTICS INC Investments/Divestments 8-K Filing

SRPT

SRPT

SAREPTA THERAPEUTICS INC

(SRPT)

2023 8-K

Show Summary

Summary

Debt Exchange Agreement

Management Change

Clinical Trials

Reduction in Force

Rights Offerings

Earnings Announcement

Credit Agreement

Financial Results

Collaboration Agreement

Amendment to Incentive Plan

Financial Results

FDA Approval of ELEVIDYS

Annual Meeting Results

External Links:

Sarepta Therapeutics disclosed the wholesale acquisition cost of its gene therapy product for the treatment of Duchenne muscular dystrophy in an investor webcast.

AI Assistant

SAREPTA THERAPEUTICS INC

2023

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.